|
|
HIV Update 2002 (7): JulyPublished by: Datamonitor Published: Oct. 3, 2002 - 21 Pages Table of ContentsOverview Introduction The monthly HIV update provides Datamonitor's assessment of the key market events that took place during July 2002. Key events include new product launches, clinical trial data and conference findings. Scope Key events are analyzed in the HIV market during July Coverage includes emerging market headlines, R&D pipeline data, epidemiology and disease specific factors. Report Highlights Biotech company pledges AIDS vaccine in three years. Reasons to Purchase Stay informed of all of the important market led events taking place in the HIV market Gain insight into the likely market impact of the events that took place in July 2002 in the HIV market. Report Highlights Second generation fusion inhibitor holds promise. PI boosting taken to the next level. DRIVERS AND TRENDS Latest data shows that an AIDS vaccine could be available as early as 2005. Approval of such a vaccine could conceivably alter the balance of the epidemic. However this may still be premature if the vaccine is not safe or globally applicable. Additional data from Roche shows that its second-generation fusion inhibitor could be potent and safe in HIV-infected individuals. Although this fusion inhibitor will not market till at least 2006, both physicians and patients are placing their hopes on this new class of HIV drugs. PI boosting strategies have provided physicians with an alternative means of treating patients. Conventional PI therapy, although effective has proven toxic to patients. Consequently PI boosting and double PI boosting have been investigated in various contexts in order to maximize efficacy, whilst minimizing toxicity. COMPANY HEADLINES A summary of the latest events from a company perspective Vaxgen Claims that HIV Vaccine Could be Available in 3 Years RESEARCH AND DEVELOPMENT HEADLINES A summary of the key events from a pipeline drug perspective Nonoxynol-9 Ineffective at Preventing HIV and Pregnancy Promising Phase I/II Trial Data for T-1249 Double Boost May Give Kaletra the Edge Early Trials Suggest Use for Growth Hormone in Combating HIV DISEASE SPECIFIC HEADLINES An overview of the epidemiological, research and clinical perspective HAART Benefits Manifest in Reduced HIV Hospitalisations Progression to AIDS not Influenced by Hepatitis C Infection Cost Of AIDS Care Highlighted Occupational HIV Prophylaxis Guidelines Proposed for EU Severe HAART Related Hepatotoxicity Predictable by Sex Skin Reactions Associated with CD8 Counts and Age HIV Bone Pain May be on the Increase HIV Matrix Protein Not Required for Nef-Boosted Infectivity HIV Protection May Increase HCV Infection Risk Short Term Success for Viral Suppression in Infants on HAART Early Initiation of HAART May Benefit Asymptomatic Patients with High CD4 Cell Counts Salvage Patients May Benefit from Early Viramune to Sustiva Switch Antibodies Active Against HIV Fusion Process Repeated Murabutide Injections May Be Beneficial for HIV Patients T-20 Administration Not A Cause For Compliance Concern? EMERGING MARKETS HEADLINES A summary of the key events from the emerging markets HIV Manufacturers Agree to Supply Discounted Drugs to Caribbean Simpler Treatment May Improve Proportions of Developing World HIV patients Receiving Care AbstractIntroduction: The monthly HIV update provides Datamonitor's assessment of the key market events that took place during July 2002. Key events include new product launches, clinical trial data and conference findings. Scope of the Report: * Key events are analyzed in the HIV market during July * Coverage includes emerging market headlines, R&D pipeline data, epidemiology and disease specific factors. Report Highlights: Biotech company pledges AIDS vaccine in three years. Second generation fusion inhibitor holds promise. PI boosting taken to the next level. Key Reasons to Buy this Report: * Stay informed of all of the important market led events taking place in the HIV market * Gain insight into the likely market impact of the events that took place in July 2002 in the HIV market.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||